Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumabNew data are first-of-its-kind analysis of microscopic mucosal resolution that go beyond endoscopy, setting a new potential standard for the evaluation of therapeutic responseINDIANAPOLIS, Oct. 14, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response ...

These stocks look like slam-dunk picks for growth investors.October sometimes gets a bad rap from investors. Sure, several major stock market crashes have occurred during the month in the past. However, October has actually been a pretty good month for stocks historically. Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they picked Eli Lilly (LLY 2.35%), Novo Nordisk (NVO 2.14%), and Vertex Pharmaceuticals (VRTX 1.17%).A plethora of gr ...

Eli Lilly and Company TodayLLYEli Lilly and Company$932.06 +21.37 (+2.35%) 52-Week Range$547.61▼$972.53Dividend Yield0.56%P/E Ratio114.79Price Target$979.29Add to WatchlistIn a year and a half, Eli Lilly NYSE: LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson NYSE: JNJ back in May of 2023 and hasn’t looked back since. However, much of that increase in value has come due to multiple expans ...

The latest trading session saw Eli Lilly (LLY) ending at $910.69, denoting a -0.98% adjustment from its last day's close. This move lagged the S&P 500's daily loss of 0.21%. Meanwhile, the Dow lost 0.14%, and the Nasdaq, a tech-heavy index, lost 0.05%.Shares of the drugmaker witnessed a loss of 0.12% over the previous month, beating the performance of the Medical sector with its loss of 3.28% and underperforming the S&P 500's gain of 5.94%.The upcoming earnings release of Eli Lilly will be of great interest ...

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.Dividend-paying stocks have been dominant performers in the U.S. market since 1900. Their power lies in compounding, which can substantially increase returns over time.Companies that consistently raise their dividends frequently outperform the S&P 500 over long periods. These dividend growers often feature strong fundamentals, proven business models, and management teams focused on shareholder ret ...

Eli Lilly's (LLY, Financial) stock experienced a notable movement, rising 1.71% to a price of $913.72. This surge was driven by the Congressional Budget Office (CBO) report on the potential impact if Medicare were to cover anti-obesity medications, including Eli Lilly's weight loss drug, Zepbound.The CBO estimates this Medicare coverage could increase federal spending by $35 billion from 2026 to 2034, underscoring the significant sales potential for GLP-1 drugs in the weight loss market. Investors have resp ...

The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.Most investors are aware of the vast sales potential for the effective new weight loss treatments known as GLP-1 drugs, and the market for them is still relatively quite young. On Tuesday, the Congressional Budget Office (CBO) put a number on one piece of that market's potential. As that figure was large, weight loss drug producer Eli Lilly (LLY 1.70%) saw a nearly 2% bump in its share price in response. That compa ...

Core Insights - Qinotto, Inc. has entered a research collaboration and license agreement with Eli Lilly to develop next-generation antibody-based vehicles for brain transport [1][2] - The collaboration aims to optimize the delivery of large molecule therapeutics to the brain, leveraging Lilly's expertise and technological infrastructure [2] Company Overview - Qinotto is a biopharmaceutical company focused on the central nervous system (CNS) and is developing novel transport vehicles to deliver therapeutic products to the brain [3] - The company's proprietary blood-brain barrier (BBB) platform, QinoTrans, identifies novel targets on the BBB to facilitate the delivery of large molecules that typically cannot cross this barrier [3] - Qinotto aims to create first-in-class brain delivery vehicles that will serve as the foundation for a pipeline of advanced CNS products [3]

Core Viewpoint - The Outsourcing Facilities Association has filed a lawsuit against the FDA, claiming the removal of Eli Lilly's weight loss drug from the shortage list is arbitrary and unlawful, which limits patient access to essential medications [1][2] Group 1: Lawsuit Details - The lawsuit was filed in a Texas federal court, arguing that the FDA's decision restricts patient access to vital treatments [1][2] - The plaintiffs, including FarmaKeio Custom Compounding, assert that the FDA should have provided advanced notice and sought public input before making its decision [2] Group 2: Drug Shortage Context - Eli Lilly's weight loss drug has been in shortage since 2022, prompting the FDA to allow pharmacies to produce cheaper, non-branded versions [1] - The FDA recently declared that the shortage issue has been resolved, which has led to restrictions on the compounding of these drugs by pharmacies [1] Group 3: Implications for Patients - The lawsuit underscores the impact of drug shortages on patient access and raises concerns about the transparency of the FDA's decision-making process [2] - Patients may face higher medication costs or need to seek alternative treatments due to the FDA's recent decision [2] Group 4: Eli Lilly's Response - Eli Lilly is working to improve drug supply, including the construction of a new manufacturing facility in Indiana [2] - Some compounding pharmacies may continue to produce the drug under a federal provision that allows compounding to meet specific patient needs [2]

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.Eli Lilly (LLY 1.27%) stock has climbed in the double digits over the past year thanks to its leading position in one of the highest-growth pharmaceutical markets around: weight loss drugs. Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight control. Doctors have prescribed both for the weight loss indication though, and demand has been so high that it' ...